Tailstorm Health Inc. dba Medivant Health

Has Tailstorm Health Inc. dba Medivant Health received an FDA warning letter about GLP-1 drugs?

Yes. FDA issued Tailstorm Health Inc. dba Medivant Health a warning letter naming semaglutide and tirzepatide, dated Apr 8, 2025, with the FDA subject line “Compounding Pharmacy/Adulterated Drug Products.” FDA has posted a close-out letter for that letter.

FDA records in this index name Tailstorm Health Inc. dba Medivant Health on Apr 8, 2025. It is listed on FDA’s registered 503B outsourcing facility list: Tailstorm Health Inc., Chandler, AZ.

Type named in FDA records
Compounding pharmacy, 503B outsourcing facility
FDA warning letters
1
Drug recall reports
0
Drugs named
Semaglutide, Tirzepatide
Latest record
Apr 8, 2025
503B location
Chandler, AZ
503B last inspection
Aug 28, 2026
Form 483 issued
Yes
Action on last inspection
Open

FDA warning letters

Later letters FDA listsLetter
Apr 8, 2025Compounding Pharmacy/Adulterated Drug ProductsSemaglutide, TirzepatideClose-out letter, Apr 14, 2026fda.gov

A warning letter states FDA’s view when it was issued; it is not a court finding, and the company may have responded since. The later-letters column repeats what FDA’s warning letter index lists for each letter.

FDA’s summary excerpts

Drug recalls

No openFDA drug recall reports in this index.

FDA compounding inspections and actions

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists 2 facilities under this exact legal name. These entries cover all of the facility’s compounding, not only GLP-1 drugs.

Tailstorm Health, Inc., Chandler, AZ (503B)

5 listed actions, including 3 Form 483s and 1 untitled letter (2021 to 2026).

Document
Aug 28, 2026Form 483483 Issued 08/28/2026fda.gov
May 23, 2025Form 483483 Issued 05/23/2025fda.gov
Oct 23, 2023FMD-145 letterFMD-145 Letter Issued 10/23/2023Not linked by FDA
Jun 17, 2022Untitled letterUntitled Letter Issued 06/17/2022FDA copy (archived)
Jul 21, 2021Form 483483 Issued 07/21/2021FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

Tailstorm Health, Inc., Phoenix, AZ (503B)

6 listed actions, including 2 Form 483s, 1 warning letter and 1 warning letter close-out (2024 to 2026).

Document
Mar 23, 2026Warning letter close-outWarning Letter Close Out Issued 03/23/2026fda.gov
Mar 20, 2026FMD-145 letterFMD-145 Letter Issued 03/20/2026Not linked by FDA
Mar 19, 2026FMD-145 letterFMD-145 Letter Issued 03/19/2026Not linked by FDA
Nov 14, 2025Form 483483 Issued 11/14/2025fda.gov
Apr 8, 2025Warning letterWarning Letter Issued 04/08/2025fda.gov
Oct 10, 2024Form 483483 Issued 10/10/2024FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

Pharmacy pages with the same legal name, built from FDA’s 503B list and compounding inspections and actions page: Tailstorm Health Inc., Chandler, AZ, Tailstorm Health, Inc., Phoenix, AZ.

FDA NDC listings

FDA’s NDC Directory files, read Nov 15, 2026, list 11 products naming semaglutide and tirzepatide under the labeler name “Tailstorm Health INC”, matched to this company page by exact name. Marketing categories as FDA gives them: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS) (11). The compounded product reports cover FDA reporting periods 2024-2 to 2025-1.

Reporting periods
81483-0045SEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS.25 mg/.05 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81483-0046SEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS.5 mg/.1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81483-0047SEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS1 mg/.2 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81483-0048SEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS1.7 mg/.22 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81483-0049SEMAGLUTIDESEMAGLUTIDEINJECTIONSUBCUTANEOUS2.4 mg/.3 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81483-0050TirzepatideTirzepatideINJECTIONSUBCUTANEOUS2.4 mg/.1 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81483-0051TirzepatideTirzepatideINJECTIONSUBCUTANEOUS5 mg/.2 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81483-0052TirzepatideTirzepatideINJECTIONSUBCUTANEOUS7.5 mg/.3 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81483-0053TirzepatideTirzepatideINJECTIONSUBCUTANEOUS10 mg/.2 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81483-0054TirzepatideTirzepatideINJECTIONSUBCUTANEOUS12.5 mg/.25 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs
81483-0055TirzepatideTirzepatideINJECTIONSUBCUTANEOUS15 mg/.3 mLOUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)2024-2, 2025-1Compounded drugs

FDA: “Outsourcing facilities that have elected to assign NDCs to their products provide FDA with a list of drugs they compounded during the previous six-month period upon initial registration and in June and December each year.” The compounded file gives no marketing dates; its reporting period is shown as FDA writes it.

FDA says: “Assignment of an NDC number does not in any way denote FDA approval of the product.” All GLP-1 NDC listings.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.